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Abstract: Neuroblastoma is the most frequent extracranial solid tumour in children, causing 10% of all
paediatric oncology deaths. It arises in the embryonic neural crest due to an uncontrolled behaviour
of sympathetic nervous system progenitors, giving rise to heterogeneous tumours. Low local or
systemic tissue oxygen concentration has emerged as a cellular stimulus with important consequences
for tumour initiation, evolution and progression. In neuroblastoma, several evidences point towards
a role of hypoxia in tumour initiation during development, tumour cell differentiation, survival
and metastatic spreading. However, the heterogeneous nature of the disease, its developmental
origin and the lack of suitable experimental models have complicated a clear understanding of the
effect of hypoxia in neuroblastoma tumour progression and the molecular mechanisms implicated.
In this review, we have compiled available evidences to try to shed light onto this important field.
In particular, we explore the effect of hypoxia in neuroblastoma cell transformation and differentiation.
We also discuss the experimental models available and the emerging alternatives to study this
problem, and we present hypoxia-related therapeutic avenues being explored in the field.
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1. Introduction
Neuroblastoma (NB) is a paediatric solid tumour arising from the neural crest (NC) during
sympathetic nervous system (SNS) development [1]. The NC is a migratory and multipotent embryonic
cell population that gives rise, among other tissues, to the SNS [2]. Despite its low frequency, NB is
the most common malignant extracranial solid tumour in children, and it is the cause of 10% of
total child cancer deaths [3]. This cancer is characterised by great heterogeneity, including some
very aggressive metastatic tumours which present poor response against conventional therapies and
frequent relapses [4].
Local or systemic low oxygen exposure (hypoxia) has been linked to NC development, including
neural crest cells (NCCs) migration and differentiation. Hypoxic conditions in the intratumoural
microenvironment lead to the deregulation of multiple cellular processes, including cell proliferation,
cell survival and cell invasion, generally leading to tumour aggressiveness and resistance to therapy.
Despite a growing number of evidences, there is still little consensus related to the effect of hypoxia
in NB initiation and progression. In this review, we summarise the main findings regarding hypoxia
and the origin, progression and malignisation of NB. We also make an overview of the tools
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available for the study of this phenomenon and provide insights into possible therapeutic approaches
under development.
2. Approaches to the Study of Hypoxia in Neuroblastoma
NB is a heterogeneous disease, with high intertumoural and intratumour heterogeneity, including
genetic and functional diversity of cells, as well as a diverse tumour microenvironment [5]. The study
of the effects of hypoxic conditions on tumour initiation and tumour progression should take into
account this emerging reality. The experimental models available for the study of hypoxia in tumours,
and in particular in NB, greatly affect the results obtained. Moreover, differential set ups should be used
to study its influence in tumour initiation, progression or metastasis. Currently available NB models
comprise genetically engineered mouse models (GEMMs), patient-derived models (patient-derived
xenografts, PDXs) and cell lines derived from them or immortalised in culture from patients’ samples.
In addition, developmental models such as chick embryo and zebra fish have proven useful to study
the generation of NB from the neural crest.
Usually, two main methods are used for controlling O2 concentration exposition in cell culture
or in vivo experiments: environmentally controlled chambers for cells or experimental animals, or a
biochemically induced state of pseudohypoxia, mostly by using cobalt chloride [6]. The study of
hypoxia in vitro on cultured cells offers ample opportunities of analysis and manipulation in a stable
environment but reflects the heterogeneity and physiology of a patient tumour poorly, and ignores
nutrient deprivation, tumour–stromal–extracellular matrix (ECM) interactions, and angiogenesis. Most
knowledge obtained so far has been derived from experiments performed on cultured cells.
NB GEMMs are a powerful tool to study tumour heterogeneity and to follow tumour evolution.
In addition, spontaneous tumour formation can be tracked. Nonetheless, tumour formation and
evolution in GEMMs is inherently associated with genomic aberrations introduced and with their
induced specific secondary genetic events. The best-known NB GEMM used to date is the tyrosine
hydroxylaseTH-MYCNmodel, a transgenic mouse that expressesMYCN (neuroblastoma-derived-v-myc
avian myelocytomatosis viral related oncogene) under the control of the rat TH promoter, activated
during development, and its derived versions [7,8]. This model has proven useful for stepwise
mechanistic analysis of the interaction between tumour and its vascular compartment and for the study
of angiogenesis, which makes it a promising model to study hypoxia and tumour progression in NB [9].
Although the TH-MYCN model has been shown to recapitulate the features of MYCN amplified human
tumours, it presents some drawbacks, such as a variable tumour incidence depending on background
and a low incidence of metastasis. These characteristics impose difficulties for some hypoxia-related
studies. New spontaneous NB tumour models are needed. For instance, a TH-MYCN/Casp8−/− mouse
model has shown a higher incidence of bone marrow metastasis and more new models are appearing
with promising results [10].
The study of hypoxic events in NB tumour initiation presents special challenges. Very little
is known about these early hypoxic events. Moreover, the lack of recurrent somatic mutations
complicates the generation of meaningful models. It would be desirable to enhance the TH-MYCN or
other transgenic mouse models to be able to follow malignant NC cells during their transformation.
Chick embryo or zebrafish models of NC development are useful for early events but do not offer a
tumour progression close enough to humans. Recently, new primary NB cell lines have been developed
by conditional reprogramming of cells cultured from TH-MYCN mice tumours recapitulating the
heterogeneous phenotypes present in tumour populations [11]. This could prove a useful tool to study
tumour initiation in the interphase between in vitro and in vivo.
PDXs are likely the most encouraging model for studying the biology of human NB, including
their response to hypoxia. Although the use of PDXs for this type of studies has been limited in
scope and number, patient-derived orthotopic xenografts (PDOXs) retain geno- and phenotypes of
patient tumours and metastatic patterns, recapitulating most of the microenvironmental hallmarks of
aggressive patient tumours, despite lacking a complete host immune system [12]. Therefore, PDOXs
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could be an optimal model for studying hypoxia during NB tumour engraftment and progression.
In addition, given the links between hypoxia and NB cell differentiation, it is useful to work in a
tumour model where the original tumour heterogeneity can be maintained and is not constrained by
the particular genetic driver of GEMM models [13].
Due to the cost and infrastructure requirements for the use of PDOXs, there is an interest in
generating cell-based culture systems derived from patient samples that can mimic most patient tumour
characteristics without compromising versatility. The generation and propagation of tumour spheroids
and the establishment of NB organotypic cultures are suitable alternatives under development [14,15].
While in vivo studies using PDXs are not compatible with high throughput analysis, the use of 3D
cultures may fill the gap between monolayer cell culture assays and model animal experiments,
as seen in Figure 1. Various devices for the specific study of hypoxia in cells, tissues and their
microenvironment have been developed [16]. Hopefully, the combination of all these complementary
models will give us a clearer idea of the mechanisms and processes involved in NB progression affected
by oxygen concentration.
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sympathoadrenal lineage aetiology derived from the NC. Thus, NCCs have been described to be the 
precursors of this malignancy. Failures of NCC migration or differentiation mechanisms are thought 
to result in the development of NBs. Different genetic events have been described to be related with 
NB initiation; for example, chromosomal aberrations such as MYCN amplification, chromosome 11q 
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Figure 1. Experi ental approaches for the study of hypoxia in neuroblasto a. Connecting olecular
characterisation with information directly obtained from in vivo assays in hypoxia chambers and/or
in vitro cultured spheroids would allow the generation of relevant evidence-driven hypothesis.
3D systems can be used for ex vivo or in vitro testing. Decreased oxygen concentration is symbolized
in the illustration as red arrow pointing down or color gradient blue to red. Green arrows denote
possible workflows.
3. Hypoxia and the Origin of Neuroblastoma
NCCs are formed at the border of the neural plate, where they undergo epithelial–mesenchymal
transition (EMT) processes, leaving the neuroepithelium in the delamination phase to migrate all
over the embryo. Once they reach their destination, NCCs differentiate into many different cell types:
pigment cells, sympathetic neurons, glial derivatives, smooth muscle cells, odontoblasts, or adipocytes.
Most NBs are found in the adrenal medulla or sympathetic ganglia, organs with a sympathoadrenal
lineage aetiology derived from the NC. Thus, NCCs have been described to be the precursors of this
malignancy. Failures of NCC migration or differentiation mechanisms are thought to result in the
development of NBs. Different genetic events have been described to be related with NB initiation;
for example, chromosomal aberrations such as MYCN amplification, chromosome 11q region loss or
17q gain. More recent research points to somatic mutations in genes such as anaplastic lymphoma
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kinase (ALK), phosphatase and tension homolog (PTEN) or alpha thalassemia/mental retardation
syndrome X-linked (ATRX), among others [2,17].
Deregulation of blood oxygen levels during embryonic development can interfere with neural
crest-derived tissue maturation. The relevance of hypoxic events during normal embryonic and foetal
development affecting placentation, angiogenesis and haematopoiesis has been widely described [18,19].
Hypoxia regulates the amount of neural crest migrating cells in a chick embryo model [20].
The expression in NC migrating cells of genes involved in NCC delamination, such as SNAIL2, SOX10
or C-X-C chemokine receptor type 4 (CXCR4), was higher under hypoxic conditions, stimulating
the migration of NCC. Hypoxia seems to induce proliferation in rat neural crest stem cells [21].
Both phenomena were dependent on hypoxia inducible factor 1 alpha (HIF-1α), a transcription
factor typically stabilised and activated under hypoxic conditions. HIF-1α expression is needed for
normal embryonic development and HIF-1α knock-out mice present severe neural tube defects [22].
The activation of HIF-1α by the platelet-derived growth factor 1 alpha (PDGF1α) and phosphatidyl
inositol kinase 3/phospho alpha serine-threonine protein kinase (PI3K/AKT) signalling pathway is also
required for NCC EMT and migration, as shown in Xenopus and zebrafish embryo models [23].
While HIF-1α stabilisation is normally involved in the response to hypoxia by the majority of
tissues, HIF-2α activation and stabilisation has been linked to the response to chronic hypoxia by
NCC, including NB cells [24]. HIF-2α knockout models present a variable developmental phenotype,
including vascular disorganisation, catecholamine levels reduction, bradycardia and midgestational
death. An important role for HIF-2α in SNS development has been described, participating in the
activation of aromatic L-amino acid decarboxylase (DDC) and dopamine beta-hydroxylase (DBH)
transcription in rat sympathoadrenal progenitors, resulting in a mature sympathoadrenal phenotype.
Failures in the regulation of HIF-2α result in the increment of sympathetic cells due to a reduced
apoptotic rate, giving rise to dysfunctional adrenal medulla and carotid body tissues [25].
There is preliminary evidence pointing towards a role for low oxygen levels exposition in NB
initiation during development. A clinical study about prenatal and perinatal events and neonatal risk
factors in NB showed that maternal anaemia, neonatal respiratory distress or neonatal haemolytic
disease could increase the risk of developing NB [18]. HIF-2α expression has been found in foetal
paraganglia and in a progenitor cell population in NB samples, correlating with vascular endothelial
growth factor (VEGF) expression [24]. Therefore, it has been suggested that HIF-2α deregulation could
play a role in the malignant transformation of sympathoadrenal progenitors, giving rise to NB tumours.
Hypoxia has also been related to other events connecting NC development and NB. For instance,
the frizzled class receptor 6 (frizzled-6) of the Wnt pathway, responsible for NC induction, is also
highly expressed in hypoxic areas on NB tumours [26], further linking NC development with NB and
hypoxic conditions.
Tumour hypoxia can also lead to genomic instability. Hypoxia has been widely described to be
involved in deregulation of DNA repair and damage response genes expression, reactive oxygen species
(ROS)-dependent acquired mutations, cell cycle arrest, DNA replication alterations or chromosomal
and microsatellite aberrations [27,28]. A recent study across 19 tumour types revealed a hypoxia
signature associated with high genomic instability [29]. These facts raise the question whether hypoxic
events during embryonic development could have an active role in the generation of genomic instability
events associated to NB initiation, such as the incidence of a massive chromosomal rearrangement,
known as chromothripsis [30]. For instance, hypoxia could activate the alternative neurotrophin
receptor tropomyosin-related kinase A III (TrkAIII) splicing variant that promotes genetic instability by
its interaction with the centrosome [31].
Despite the prominent role of hypoxia during NC development and emerging evidence suggesting
a role for hypoxia in NB initiation, the knowledge about this topic is still very limited and highly
speculative, due to the limited approaches to properly address NB initiation events.
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4. Neuroblastoma Differentiation and Stemness in Hypoxic Contexts
The correlation between NB tumour differentiation, prognosis and clinical outcome is well
established, with a worse outcome attributed to tumours with undifferentiated histology [32].
Furthermore, NB cellular heterogeneity, and in particular the presence of an undifferentiated neural
crest stem-like cell population, has been proposed to have a fundamental effect on tumour progression
and response to therapy [33,34]. Putative markers for cancer stem cells (CSCs) in NB have also
been described, although there is not a definitive conclusion on this matter [35]. Local oxygen
tissue concentration exerts determinant relevant roles in tumour microenvironment, affecting cell
differentiation and stemness in turn.
There has been some controversy regarding the differentiation potential of hypoxic conditions
in NB tumours. Early studies suggested that hypoxia promotes aggressive tumour behaviour in NB,
showing a neuronal-to-neuroendocrine lineage shift in cells close to non vascularised necrotic areas [36].
Works based on the morphological and molecular analysis of 116 clinical NB tumours, and supported
by hypoxia-induced phenotypes observed in vitro and in vivo, showed that hypoxic NB cells switch
from primitive neuronal to a chromaffin cell type, which was reversible upon reoxygenation [36]. These
regions were characterised by the expression of high levels of the insulin-like growth factor 2 gene
(IGF2) and low levels of the growth-associated protein-43 gene (GAP-43), expressed in chromaffin and
neuronal cells, respectively, in the foetal nervous system. Same results were obtained assessing the
expression of neuroendocrine secretory protein 55 (NESP55), a sensitive early human sympathetic
nervous system chromaffin marker, concluding that 0.5–1% O2 triggers hypoxia-mediated chromaffin
metaplasia across the clinical spectrum of neuroblastic tumours [37].
By contrast, results from other groups suggest the induction of immature, stem-cell-like features
in response to hypoxia, and associated with poor clinical outcome. Authors identify the expression
of markers for immature neural crest cells, such as inhibitor of DNA binding 2 (ID2), and the
downregulation of neuroendocrine enzymes, such as chromogranin A, in NB cells after exposition
to hypoxia [38,39]. A global gene expression analysis showed that hypoxia provoked a general
adaptive response in NB cells, confirming loss of the neuronal phenotype in favour of a gain in stem
cell genes [40]. An upregulation of proneuronal lineage specifying transcription factors inhibitors
(ID2 and HES-1) and downregulation of proneuronal lineage specifying transcription factors was
found. However, they also described the expression of genes involved in the physiological response to
low oxygen, such as TH or DDC, indicating that the response might be cell-type-dependent.
Hypoxia-induced dedifferentiation of tumour cells, as a mechanism behind cellular heterogeneity
and aggressiveness in solid tumours, has been subsequently reviewed and supported by multiple
works [41]. HIF-1α and HIF-2α have been observed to be differentially recruited to target genes
in NB in response to hypoxia, with HIF-2α preferentially promoting an aggressive phenotype [24].
HIF-2α regulates the OCT4 gene influencing stem cell function, embryonic development, and tumour
growth [42]. A perivascular niche for brain tumour stem cells has been described [43] and the brain is
one of the main metastatic sites for aggressive NB. Therefore, the existence of a perivascular niche
for NB stem cells has been explored. High levels of HIF-2α delineate an immature neural-crest-like
NB cell subpopulation, characterised by the expression of NOTCH1, HES-1, c-Kit, vimentin and
dHAND, and located in a perivascular niche [44]. This hypoxia-inducible factor has been associated
with increased invasion, tumourigenicity and stemness [45]. A meaningful function for HIF-2α in
maintaining an undifferentiated state in neural-crest-like human NB tumour-initiating cells has been
proposed [46]. It seems clear that HIF-2α protein levels in NB, as well as an immature phenotype,
correlate with an unfavourable outcome, although potential hypoxia-independent functions of HIF-2α,
related to aggressiveness, have also been suggested. Proteomic analysis in NB cells shows that increased
hypoxia-independent HIF-2α expression correlates with an increment of fatty acid storage and a shift
in global splicing regulations that has been previously reported in high-risk tumours [47,48].
Global gene expression analysis has also been used to investigate the relationship between
hypoxia and NB progression, particularly analysing the role of HIF-2α. In support of the induction
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by hypoxia of immature stem-cell-like features contributing to a malignant phenotype in NB,
Applebaum et al. integrated diverse transcriptomics datasets from NB tumours and cell lines,
identifying a hypoxia-upregulated signature correlated with poor patient outcome in three independent
cohorts [49]. The signature included the expression of LCO4A1, ENO1, HK2, PGK1, MTFP1, HILPDA,
VKORC1, TPI1, andHIST1H1C.They experimentally validated the findings demonstrating upregulation
in response to hypoxia in four NB cell lines. Other hypoxia-related gene signatures have been used
to predict patient outcome, with poor outcomes for patients with hypoxic tumours, supporting the
potential of using hypoxia-related pathways as targets for NB treatment [50,51].
On the other hand, a recent study suggests that HIF-2α expression correlates with features of
low-risk NB and with adrenal chromaffin cell differentiation [52]. In this work, HIF-2α high expression
correlates with significantly increased overall survival and with genes associated with differentiation
and better patient outcome. In addition, treatment with HIF-2α inhibitors did not block in vitro NB
cell proliferation or xenograft tumour growth. Single cell sequencing data from the developing mouse
sympathoadrenal lineage has allowed the elucidation of the cellular compartments presenting high
levels of Hif-2α [53]. This analysis suggests that HIF-2α expression is generally high in chromaffin
differentiated cells and in low risk, MYCN nonamplified tumours, precluding its consideration as an
oncogene in NB.
This controversy in the field might be clarified in light of emerging studies highlighting the cellular
heterogeneity present in NB, and demonstrating the presence of different transcriptomic circuits
in phenotypically different NB cell populations [33,54]. In general, and despite the contradictory
results involving HIF-2α, hypoxia seems to evoke a more aggressive NB phenotype, favouring the
undifferentiated immature state of stem-like cells and correlating with poor prognosis and worse
patient outcome. However, hypoxia might also promote a switch to mature chromaffin cells in a
different, more determined, cell population. Given the transcendence of undifferentiated cancerous
cells in tumour evolution, it would be essential to study if their persistence could be favoured by
hypoxic environments during cancer initiation and progression.
5. Hypoxia and NB Cell Survival
Hypoxic conditions in intratumoural microenvironments lead to the deregulation of multiple
cellular processes. Experimental and clinical data associate cellular response to hypoxia with tumour
aggressiveness and resistance to therapy in many cancer types, which is linked with higher proliferation
rates and apoptosis bypass [55].
A global gene expression analysis performed in NB-derived cells under normoxic/hypoxic
conditions found upregulation by low oxygen of cell survival and growth related genes such
as VEGF, NEUROPILIN 1, ADRENOMEDULLIN and IGF2, among others [39]. IGF-1 and IGF-2
upregulation, together with the expression of VEGF, was proposed as a possible activation of an
autocrine signalling loop that would allow cells to overcome low oxygen concentration in the hypoxic
tumour microenvironment. A transient cell cycle arrest, but no increase in cell death, was described
after hypoxic exposition in SK-N-BE NB cells. Cell cycle arrest has been described in renal clear
cell carcinoma (RCC) and colon cancer cell lines in relation to HIF1-α stabilisation. On the contrary,
HIF-2α stabilisation was described to drive cell cycle progression in RCC cells in a c-myc dependent
manner [56]. However, not enough data is available regarding hypoxia and proliferation in NB.
A relationship between MYCN amplification and HIF-1α expression driving high proliferation has
been suggested, although the connection with hypoxia has not been established [57].
More information exists on hypoxia-related apoptosis resistance. Hypoxia exposition for more than
12 hours has been described to induce apoptosis in PC12 cells, but HIF-1α activation would promote
antiapoptotic pathways via caspase 3 and Ras homolog family member A (RhoA) activation [58].
No change in Ras homolog family member (RhoB) expression after hypoxia was found in this
study, which is in contradiction with other published data [59]. MYCN amplification has been
described to correlate with HIF1-α stabilisation, exerting a possible antiapoptotic effect through
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Survivin upregulation [60]. VEGF expression in response to hypoxia has been described to trigger
apoptosis resistance in NB cells by the upregulation of B cell leukaemia 2 (Bcl-2) expression and
extracellular-signal-regulated kinase (ERK1/2) phosphorylation [61–63]. ERK1/2 was found also to
phosphorylate HIF-1α, keeping VEGF expression in an autocrine-loop.
This resistance to apoptosis might be partially responsible for chemoresistance associated with
hypoxic conditions in cancer cells [64]. Cellular adaptation to hypoxia provokes HIF-1α-mediated
resistance to chemotherapeutic agents [65,66]. NB cells adapt to hypoxia by HIF1-α-dependent and
HIF1-α-independent responses. HIF1-α driven transcriptional response in hypoxia is a consequence of
the epigenetic control of low oxygen levels at DNA methylation status in intragenic and intergenic
regions [67–69]. Therapy resistance in cancer cells could be triggered by many different cellular events,
such as emergence of DNA instability, drug metabolism, drug eﬄux, cell cycle arrest or apoptosis
inactivation. Hypoxia has been described to drive misregulation of DNA repair and damage response
genes, such as Ataxia Telangiectasia mutated (ATM) or ATRX, in cancer cells, and has been shown
to increase rates of mutations due to intracellular ROS production [61]. Cell cycle hypoxia-related
deregulation could also lead to aberrant proliferation of damaged cells, making them susceptible
to acquired drug-resistance. Metallothioneins, proteins related to drug resistance, have been found
to be induced under hypoxic conditions in NB cell lines [40]. p53 is barely mutated in NB, but it is
believed that p53 response inactivation could be associated with relapses and multidrug resistance [70].
Furthermore, both p53 and HIF1-α are degraded/stabilised, respectively, by murine double minute
2 (MDM2), and it has been proposed that these two factors together could be interplaying in some
way [71]. p53 has been described to be activated under hypoxia, thus increasing apoptosis. However,
loss of sensitivity to p53-mediated apoptosis could occur further downstream in the signalling cascade.
6. Hypoxia and Metastasis in Neuroblastoma
In NB, metastatic disease is detected in approximately 50% of patients at diagnosis, frequently in
the regional lymph nodes, bone marrow and bone [72]. Hypoxia is linked to metastasis, but how it
affects metastatic progression is not clear due to limited consensus in the literature. Sustained hypoxia
in a growing tumour seems to be associated with increased invasive capacity, perifocal tumour cell
spreading and regional and distant dissemination, resulting in a clinically aggressive phenotype [55,73].
Hypoxia can also decrease motility speed, while increasing invasiveness and directionality, and even
induce a dormancy-like program [74,75]. The molecular mechanisms responsible for these effects are
not completely understood.
On NB, the number of published works dealing with this topic is low. In NB cells, hypoxia
promotes the expression of TRIO and SERPINB9 [24], genes thought to be involved in metastasis
in other cancers [76–79]. A prometastatic gene expression program activated by hypoxia in NB
cells has been described [80]. In vitro experiments using chemically induced hypoxia showed the
downregulation of genes involved in maintenance of cell–cell and cell–matrix interactions, such as
metalloprotease-4 inhibitor (TIMP4), E-cadherin (CDH1), catenin (CTNNB1) and fibronectin-1 (FN1).
In contrast, metastatic behaviour genes, including integrin α7β1 (ITGA7), hepatocyte growth factor
receptor (HGFR), transforming growth factor-β1 (TGFβ1), VEGF and interleukin-1β (IL1B) were
upregulated under the same conditions. Hypoxia seems to contribute in NB cells to invasiveness
through HIF-1α via sonic hedgehog signalling (SHH) [81]. Blockage of SHH signalling and the
glioma-associated oncogene (GLI) transcription factor could be an effective way to target high-risk
metastatic NB [82]. In vitro experiments show that HIF-1α enhances NB cell migration under hypoxic
conditions maybe through a mechanism involving matrix metalloproteinases (MMPs) [81].
The effect of hypoxia in metastasis can be better highlighted by in vivo experiments, when a
real microenvironment is in place. Experiments performed on chick embryos showed that hypoxia
provokes NB cell invasion and metastasis. Furthermore, invasion by nonmetastatic cells can be
triggered by close contact with metastatic cells [83]. Hypoxia preconditioning was sufficient to activate
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the long-lasting transcription of several prometastatic genes, including MMP2, TWIST1, SNAIL1 and
CDH1. HIF activity was indispensable for the acquisition of the metastatic phenotype.
Most studies pointing towards a possible involvement of hypoxia regulation in NB metastasis
are indirect and come from the observation of HIF-dependent effects. For example, overexpression of
MDM2 leads to increased HIF-1α transcriptional activity, while in vitro inhibition provokes decreased
transcription of downstream targets [84]. Under hypoxic conditions, Nutlin-3a, a specific MDM2
inhibitor, suppresses HIF-1α expression, leading to p53-independent inhibition of VEGF [85]. Nutlin-3a
also significantly reduced the incidence of NB metastasis in vivo. Isatin, an inhibitor of monoamine
oxidase (MAO), which in turn stabilises HIF-1α, inhibits cell invasion and metastasis in NB through a
mechanism involving the SDF1/CXCR4 axis [86]. It is, however, unclear whether this mechanism is
regulated in any way by hypoxia. In NB, microRNA-145 (miR-145) induces HIF-2α repression, thus
promoting downregulation of downstream cyclin D1, MMP14 and VEGF [87]. miR-145 suppresses
NB cell growth, invasion and angiogenesis in vitro and inhibits metastasis in vivo in a HIF-2α
dependent manner.
So far, despite the accepted view of hypoxic conditions affecting metastasis, including in NB,
the molecular mechanisms surrounding these effects have been poorly elucidated. In this sense,
limitations of the standard assays used to evaluate hypoxia in cancer and metastasis, mostly based on
in vitro approaches, are a major handicap.
7. Hypoxia-Related Therapies
As discussed in this review, hypoxic events could have a fundamental impact on NB initiation,
progression and metastasis. The finding of new targets and development of new therapeutic approaches
is a main concern in the field. The lack of suitable, standardised in vivo models and the little knowledge
about the mechanisms involved hinders more rapid progress. One of the best described effects
of hypoxia in tumours is the triggering of an aggressive angiogenic response. Blocking tumour
angiogenesis has been one of the most studied therapeutic approaches in recent years [88]. In NB,
HIF-2α positive cells, expressing immature neural crest cell markers, were found in a perivascular
niche; therefore, targeting them with antiangiogenic therapy arose as a new treatment strategy, with
some success in vivo [89,90]. Many studies have focused on VEGF targeting as one of the most
relevant approximations. Indeed, suppressive expression of VEGF has been described to increase the
effectiveness of cytotoxic Irinotecan treatment in NB animal models [91]. Targeting of VEGF with the
receptor-tyrosine kinase (RTK) inhibitor Sunitinib has been shown to be effective in NB metastatic
cell treatment, but no change in resistance to this therapy has been found in clinic [92]. Sunitinib has
been combined in another study with Evofosfamide, a cytotoxic prodrug activated under hypoxia,
showing enhanced effectivity in tumour growth suppression [93]. However, antiangiogenic therapies
have been shown to trigger metastasis in some models, precluding the general use of this approach at
this point [90].
Some authors have suggested HIF targeting as a viable strategy to overcome resistance to therapy.
HIF-1α expression decreases after Sunitinib treatment and HIF-1α activation has been described
in cells resistant to different therapies [94]. In NB, HIF-2α has been more directly related to poor
prognosis. HIF-2α inhibition leads to VEGF reduction [95]. The introduction of HIF inhibitors into
differentiation therapy protocols might offer therapeutic advantages for relapse prevention. Indeed,
the combination of all-trans retinoic acid (ATRA) with HIF-1α or HIF-2α silencing leads to an acquired
glial cell phenotype and enhanced expression of glial cell differentiation markers. HIF-1α or HIF-2α
silencing might also promote cell senescence independent of ATRA treatment [96]. However, some
reports link HIF-2α inhibition to a decreased tumour response to treatment [97]. Thus, the targeting of
HIF-2α in NB tumours is still a questionable strategy. More detailed studies related to the targeting of
hypoxic zones in the tumour and hypoxia cellular response mechanisms are needed to advance in
this direction.
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8. Future Perspectives
Understanding the molecular mechanisms involved in NB initiation and progression is a major
concern in order to improve the prognosis and treatment of this devastating disease. The data
available supports the idea of hypoxia having an impact in NB development, NB cell fate and
metastasis activation, among other processes, as seen in Figure 2 and Table 1. However, there is still
great controversy about the role of hypoxia in NB cell differentiation, cell survival balance or NCCs
malignant transformation. Furthermore, therapeutic approaches targeting hypoxia-related processes
tend to fail in the clinic due to emerging resistance mechanisms.
1 
 
 
Figure 2. Effects of hypoxia in NB initiation and progression. (A) Neural crest (NC) migrating
cells can undergo malignant transformation due to hypoxia exposition or disregulation, driving
tumourigenesis. (B) A neuroblastoma (NB) tumour is comprised of phenotypically divergent cells.
Hypoxia might favour malignant progression in NB tumours, characterised by the activation of
angiogenesis, alteration of cellular differentiation, tumour cell survival and resistance and an increase
of metastasis. The extracellular matrix is also affected by hypoxia. NB: neuroblastoma; NCC: neural
crest cell; ADR: adrenergic cells, MES: mesenchymal undifferentiated cells; TPC: Undifferentiated
tumour-propagating cells. Blue arrow in box denote an increase.
Deeper knowledge about the molecular mechanisms underlying hypoxia response in NB cells
is needed to fully understand the biology of the disease and provide new therapeutic opportunities.
For that, the development of new laboratory models and tools, including the use of in vivo models
of hypoxia and 3D in vitro cellular assays, would be necessary in order to clarify the contradictory
results obtained in divergent cellular models. These approaches should consider the important
relevance of intratumour cellular heterogeneity to delineate population-specific responses to hypoxia.
In particular, the elucidation of the effects of hypoxia exposition in the phenotype and character of the
undifferentiated NB neural crest stem-like cell population would help clarify the role of hypoxia, both
in NB initiation and in malignant progression.
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Table 1. Hypoxia-mediated gene-expression regulation in neuroblastoma.
Cellular Processes Genes References
Initiation ↑ HIF-1α, HIF-2α, SNAIL-2, SOX10, CXCR4, PDGF1-α,FZD-6, TRKAIII [21–23,25,26,31]
Differentiation
↑ IGF-2, NESP55, ID2, HES-1, TH,
DDC, HIF-2α, OCT4, NOTCH1,
c-Kit, Vimentin, dHAND
↓ GAP-43, CHGA [37–39,42,44]
Cell survival
↑ HIF-1α, HIF-2α, VEGF, NEUROPILIN 1,
ADRENOMEDULLIN, IGF-1, IGF-2, RHOA, BCL-2,
Survivin, Methallothioneins, p53, MDM2
[39,54,56,58–61,68]
Metastasis
↑ VEGF, TRIO, SERPINB9, ITGA7,
HGFR, TGFβ1, IL1B, MMP2,
TWIST1, SNAIL1, CDH1, HIF-1α
↓ TIMP4, CDH1,
CTNNB1, FN1 [24,39,74–79,81]
Malignant phenotype ↑ LCO4A1, ENO1, HK2, PGK1, MTFP1, HILPDA,VKORC1, TPI1, HIST1HIC [49]
Arrow pointing downwards: decrease in expression. Arrow pointing upwards: increase in expression.
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